These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 29989854)

  • 21. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.
    Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA;
    BMJ Open; 2017 Jan; 7(1):e014439. PubMed ID: 28119394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
    Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
    Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
    Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
    Ohashi K; Hotta K; Hirata T; Aoe K; Kozuki T; Ninomiya K; Kayatani H; Yanai H; Toyooka S; Hinotsu S; Takata M; Kiura K
    Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study.
    Shitara K; Honma Y; Omuro Y; Yamaguchi K; Chin K; Muro K; Nakagawa S; Kawakami S; Hironaka S; Nishina T
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):5-13. PubMed ID: 31721447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
    Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer.
    Tataroglu Ozyukseler D; Basak M; Ay S; Koseoglu A; Arıcı S; Oyman A; Sürmeli H; Turan M; Turan N; Odabaş H; E Yıldırım M
    J Oncol Pharm Pract; 2021 Apr; 27(3):547-554. PubMed ID: 32423326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
    Takahashi K; Ishibashi E; Kubo T; Harada Y; Hayashi H; Kano M; Shimizu Y; Shirota H; Mori Y; Muto M; Ishioka C; Dosaka-Akita H; Matsubara H; Nishihara H; Sueoka-Aragane N; Toyooka S; Hirakawa A; Tateishi U; Miyake S; Ikeda S
    Medicine (Baltimore); 2020 Aug; 99(32):e21457. PubMed ID: 32769873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
    Montemurro F; Delaloge S; Barrios CH; Wuerstlein R; Anton A; Brain E; Hatschek T; Kelly CM; Peña-Murillo C; Yilmaz M; Donica M; Ellis P
    Ann Oncol; 2020 Oct; 31(10):1350-1358. PubMed ID: 32634611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
    Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
    J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
    Parikh A; Atreya C; Korn WM; Venook AP
    J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
    Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
    Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.